CYP2C19

Inflammation-driven variability in drug metabolism: Insights from voriconazole treatment of HSCT recipients

Voriconazole après greffe de cellules souches hématopoïétiques — phénoconversion par inflammation

Paradoxical myocardial infarction risk with dual antiplatelet therapy in East Asian ischaemic stroke: a nationwide real-world cohort study and pharmacogenomic risk prediction model

Prévention secondaire de l'AVC ischémique — bithérapie antiplaquettaire et *CYP2C19* en population est-asiatique

Pharmacogenetic phenoconversion modeling of drug-drug-gene interactions on CYP2C19 activity: effects of comedication by genotype on escitalopram concentrations

Escitalopram — modélisation des interactions médicament-médicament-gène sur l'activité *CYP2C19*

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation.

Syndrome coronarien aigu sous clopidogrel — effet pronostique du génotype CYP2C19 différent selon le sexe

CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping

Génotypage *CYP2C19* au point d'intervention — dosage CRISPR

High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease.

Reflux gastro-œsophagien — échec IPP, prévalence CYP2C19 métaboliseur rapide/ultra-rapide

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention.

Phénoconversion CYP2C19 sous inhibiteurs médicamenteux après angioplastie coronaire

Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome: A Combined Analysis

Syndrome coronarien aigu (SCA) — risque de MACE sous clopidogrel

Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.

Effets indésirables des inhibiteurs sélectifs de la recapture de la sérotonine

Exposure to CYP2C19-metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing.

AVC ischémique — exposition aux substrats du CYP2C19

The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke

Résistance au clopidogrel — AVC ischémique récurrent

Evaluation of a pantoprazole and 4-desmethylpantoprazole-sulfate metabolic ratio as a novel CYP2C19 phenotyping method

CYP2C19 phénotypage fonctionnel — validation du ratio métabolique pantoprazole/4-desméthylpantoprazole-sulfate comme sonde de phénotypage

Genotype influences antidepressant discontinuation in a pre-emptive pharmacogenetic testing population.

Dépression / Anxiété

CYP2C19 genotype-guided antiplatelet therapy to prevent thromboembolic events after stent-assisted coil embolization of unruptured intracranial aneurysms: a retrospective cohort study.

Anévrisme intracrânien non rompu traité par embolisation assistée par stent

Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature.

Sous-implémentation de la pharmacogénétique du clopidogrel en cardiologie

Pharmacogenomic Profiling of Voriconazole Enables Predicting Its Toxicity in Pediatric Leukemia and Hematopoietic Stem Cell Transplant Recipients.

Toxicité du voriconazole chez l'enfant avec leucémie ou greffe de cellules souches — prédiction par génotype CYP2C19

Influence of combined CYP2C19 and CYP2D6 phenotypes on adverse drug reactions in patients with major depressive disorder: a clinical cohort study

Dépression majeure (MDD) — effets indésirables des antidépresseurs

Identification and functional characterization of 11 novel CYP2C19 variants in the Chinese Han population

Variations métaboliques CYP2C19 — nouveaux allèles dans la population Han chinoise

Challenges and prospects of CYP2C19 genotype-guided clopidogrel therapy from the perspective of precision medicine

Thérapie antiplaquettaire post-PCI — débat sur la généralisation du génotypage CYP2C19

Pharmacogenomic landscape in Thailand: Array-based profiling and EMR-linked medication exposure

Implémentation de la pharmacogénomique en population thaïlandaise

Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.

Traitement antiplaquettaire double après angioplastie coronaire

A primary care pharmacogenetic precision medicine pilot based on specific Māori tribal ethical frameworks and principles

Pharmacogénétique en soins primaires — cadre éthique tribal māori

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Maladies cardiovasculaires / pharmacogénétique

Optimizing P2Y12 Inhibitor Therapy in Post-PCI Patients Through Genotype-Guided Strategies: A Systematic Review and Meta-Analysis.

Post-PCI — optimisation thérapie P2Y12 guidée par génotype CYP2C19

Voriconazole therapy and CYP2C19 phenotype: identifying patients who may need alternative antifungal therapy.

Infections fongiques invasives — voriconazole

Pre-emptive CYP2C19 genotyping and voriconazole exposure in pediatric hematology patients at risk of aspergillosis: an exploratory randomized pilot study with a cost-consequence analysis.

Exposition au voriconazole en hématologie pédiatrique

CYP2C19 c.681G>A Is not in Complete Linkage Disequilibrium With c.332-23A>G: Implications for Pharmacogenetic Testing

Interprétation du génotype CYP2C19

Integrating Clinical Evidence with PBPK Modeling to Assess PPI-Clopidogrel-CYP2C19 Interactions in Chinese ACS Patients.

Syndrome coronarien aigu — interaction IPP-clopidogrel